Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

617 - Bone metastases in non-small cell lung cancer: a retrospective study


20 Dec 2015


Poster presentation 2


Puneet Bagri


Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532


P.K. Bagri, S. Samdariya, P. Pareek

Author affiliations

  • Radiation Oncology, All India Institute Of Medical Sciences(AIIMS), 342005 - Jodhpur/IN


Abstract 617


Bone is one of the most common sites of metastasis in patients with advanced cancer. Bone metastases often cause skeletal-related events (SREs). Despite advances in the treatment of primary lung cancer, SREs still affect many patients. The aim of this retrospective study to investigate the clinical impact of SREs, and to compare differences in the therapeutic outcome between patients with and without bone metastases or SREs.


512 patients with histologically proved nonsmall cell lung cancer (NSCLC) who consulted the department of Oncology at Regional cancer institute between May 2009 and July 2011. We assessed their TNM stage, presence of bone metastases (on bone scan, CT/MRI, and plain X-ray films), and outcome parameters such as SREs, analgesic use, and survival.


A total of 164 patients (32.03%) were found to have skeletal metastases during their clinical course and 96 patients (58.54%) out of all 164 patients had SREs. Among 315 stage IV patients, a total of 147 (46.67%) had bone metastases, and 72 of these 147 patients (48.98%) had SREs. The most common SREs were the need for radiotherapy (48%). Patients with SREs tended to have worse survival, while no significant difference of survival was observed between patients with and without bone metastases.


It seems to be important to prevent SREs during the treatment of NSCLC, so further studies evaluating bisphosphonates in combination with chemotherapy are warranted.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings